Introduction {#s1}
============

The development of new cytotoxic drugs has increased the median survival time (MST) for patients with metastatic colorectal cancer (mCRC) from 8 to approximately 30 months over the past two decades.[@R1] However, *BRAF* V600E mutations occur in 8%--11% of patients with mCRC in western countries[@R4] and in 4%--6% in Japan[@R6] leading to poor prognoses and limited response to first-line fluoropyrimidine-based doublet chemotherapy plus targeted agents. The use of aggressive upfront chemotherapy with FOLFOXIRI plus/minus bevacizumab has the potential to improve prognoses.[@R8] Conversely, second-line and beyond treatments have little efficacy, with response rates (RRs) at 0%--11%, median progression-free survivals (mPFSs) at 1.5--3.5 months and MSTs at 1.8--6.7 months.[@R9] The development of new drugs is needed to improve outcomes in second-line and beyond therapies.

*BRAF* V600E mutant and wild-type tumours present different gene expression profiles. Vecchione *et al* found that *RANBP2* increased microtubule outgrowth from the kinetochores and that shRANBP2 impaired *BRAF* V600E mutant CRC cell line proliferation, but not *BRAF* and *KRAS* wild-type cell lines, suggesting that the *BRAF* V600E mutant CRC may be vulnerable to mitosis.[@R11] They also showed that only the *BRAF* V600E mutant CRC cell line had greater sensitivity to microtubule inhibitors, suggesting that microtubule inhibitors have antitumour activity against *BRAF* V600E mutant CRC cells.[@R11]

Eribulin is a microtubule inhibitor and has been used worldwide for patients with metastatic breast cancer or soft tissue tumours. Towle *et al* found that eribulin had greater growth inhibitory activity against the *BRAF* V600E mutant CRC cell line than either vinblastine or paclitaxel (IC~50~, 0.71±0.05 vs 2.4±0.02 or 7.8±1.5 nM, respectively).[@R12] Eribulin had greater growth inhibitory activity against the *BRAF* V600E mutant CRC cell line and the *BRAF* V600E mutant melanoma and breast cancer cell lines than did vinblastine or paclitaxel, suggesting that eribulin has antitumour activity against *BRAF* V600E mutant cells that are not limited to CRC.[@R12] Moreover, after analysing The Cancer Genome Atlas data, we found that the expression level of ABCB1 (ATP-binding cassette subfamily B member 1, also known as MDR1, and involved in eribulin resistance) in *BRAF* V600E mutant CRC cells was significantly lower than that in *BRAF* V600E wild-type CRC cells.[@R13] We followed four patients with *BRAF* V600E mutant mCRC treated with eribulin. One patient had a confirmed partial response (PR) with 39% decrease from baseline CT. Another one had a stable disease (SD) with 7% decrease from baseline CT and 6 months of progression-free survival (PFS).[@R13] Based on these results, we planned a multicentre phase II study of eribulin in patients with *BRAF* V600E mutant mCRC.

Study design and treatment {#s2}
==========================

This study is a multicentre, open-label, single-arm phase II study to evaluate the efficacy and safety of eribulin monotherapy in patients with *BRAF* V600E mutant mCRC ([figure 1](#F1){ref-type="fig"}). For this study, we divided patients into two study sections, one for primary analysis part and the other one for liquid biopsy parts. We identified patients as harbouring *BRAF* V600E mutant CRC based on next-generation sequencer-based and PCR-based assays using tumour tissues for the primary analysis part. Among the patients identified as harbouring *BRAF* V600E mutations based on a liquid biopsy test, we classified those showing positivity for the same mutation according to the analysis of tumour tissues into the primary analysis part and patients showing negativity for the same mutation by analysis of tumour tissues (or those unanalysable) into the liquid biopsy part ([table 1](#T1){ref-type="table"}).

###### 

Patients and study components

  --------------------------------------------------------------------------------------------------------------------------------------
  Study patients                                           Tumour tissues                                           
  -------------------------------------------------------- ---------------------------- --------------------------- --------------------
  **Blood sample**\                                        ***BRAF*****V600E mutant**   Primary analysis part       Liquid biopsy part
  **(ctDNA analysis)**                                                                                              

  ***BRAF*****V600E mutation negative or not evaluated**   Primary analysis part        Not enrolled in the study   
  --------------------------------------------------------------------------------------------------------------------------------------

ctDNA, circulating tumor DNA.

![Study design. ECOG PS, Eastern Cooperative Oncology Group Performance Status.](esmoopen-2019-000590f01){#F1}

For the primary analysis part, we will administer the protocol treatment, eribulin monotherapy, to 27 individuals in the Full Analysis Set (FAS: all enrolled patients who received at least one dose of eribulin and met eligibility criteria mentioned below) to evaluate its efficacy and safety. For the liquid biopsy part, we will administer the protocol treatment to 15 individuals at the most to evaluate its efficacy and safety. We initiated the patient enrolment in March 2018, completed the primary analysis on May 2019, and are currently continuing with the liquid biopsy analysis (a 12-month follow-up period after the last patient is enrolled). Eribulin at a dose of 1.4 mg/m^2^ is intravenously administered over 2--5 min on days 1 and 8 of a 3-week cycle. The protocol treatment is repeated until each subject meets any of the discontinuation criteria. We are conducting this study in accordance with the guidelines for Good Clinical Practice of the International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, as well as with the ethical guidelines for medical and health research involving human subjects. Patients have to provide written informed consent prior to participation.

For the translational research, we have and will collect pretreated tissues and serial blood samples at three time points (before the start of the treatment protocol, on the scheduled start day of cycle 2, and after the discontinuation of the treatment protocol) for biomarker analysis, focusing on gene expressions associated with *BRAF* mutant-like CRC as a predictive marker, on *BRAF* mutant allele frequencies in ctDNA for early efficacy detection, and on acquired gene alterations to detect resistance mechanisms to eribulin.

During our study, we will use Guardant360, a liquid biopsy test developed by Guardant Health to identify *BRAF* V600E mutations for patient screening and to evaluate acquired gene alterations for translational research in blood samples. Guardant360 includes a panel for detecting 74 cancer-associated genomic alterations with ctDNA extracted from blood samples, using a digital sequencing technology that detects single nucleotide variation with a sensitivity of 99.9% and a positive predictive value of 99.6%.[@R14]

We registered this study with the University Hospital Medical Information Network.

Patients {#s3}
========

Patients with *BRAF* V600E mutant unresectable CRCs and refractoriness or intolerance to at least one regimen (including irinotecan or oxaliplatin) containing fluoropyrimidine are eligible for inclusion. Additional eligibility criteria are listed in [box 1](#B1){ref-type="boxed-text"}.

###### Eligibility criteria

Inclusion criteria:
-------------------

-   Patients from whom voluntary written informed consent for study participation has been obtained.

-   Patients 20 years or older at the time of providing informed consent.

-   Patients with a definitive diagnosis of advanced or metastatic colorectal adenocarcinoma by histological diagnosis.

-   Patients unresponsive or intolerant to at least one of the chemotherapy regimens with fluoropyrimidines (including irinotecan or oxaliplatin) and with indications for second-line or later-line treatments.

-   Patients with *BRAF* V600E mutant colorectal cancer (CRC) diagnosed based on the result of a genetic test with relevant records available.

-   Patients with a measurable lesion based on the Response Evaluation Criteria in Solid Tumors guideline (V.1.1).

-   Patients who can provide formalin-fixed, paraffin-embedded specimens of CRC tissues collected before registration in this study.

-   Patients with Eastern Cooperative Oncology Group Performance Status of 0 or 1.

-   Patients expected to survive for at least 3 months.

-   Patients confirmed to have adequate organ function as shown by laboratory data (listed below) obtained within 7 days before registration (a test 7 days before registration, on the same day of the week, is permitted). However, patients who have received blood transfusion or haematopoietic factor products, such as granulocyte colony-stimulating factor products, within 7 days before the test are excluded.

-   Women of child-rearing age who test negative in a urine pregnancy test conducted within 14 days before registration (a test conducted 14 days before registration, on the same day of the week, is permitted). When the urine test indicates a positive result or does not confirm a negative result, a serum pregnancy test will be conducted to confirm a negative result. Both men and women should have agreed to use appropriate contraceptive measures from the day of providing their informed consent and up to 90 days after the last dose of the investigational drug.

    -   Neutrophil count ≥1500/mm^3^.

    -   Platelet count ≥1 00 000/mm^3^.

    -   Haemoglobin (Hb) ≥90.0 g/L.

    -   Serum creatinine ≤1.5 mg/dL or calculated or measured creatinine clearance ≥50 mL/min.

    -   T-Bil ≤1.5 mg/dL.

    -   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤100 IU/L or ≤150 IU/L in the case of liver metastasis.

    -   Resolution of diarrhoea, oral mucositis, peripheral sensory neuropathy, nausea and fatigue, which are adverse events to prior treatments, to grade 1 or below.

Exclusion criteria:
-------------------

-   Patients with a history of treatment with eribulin.

-   Patients with symptomatic brain metastasis or meningeal dissemination.

-   Patients with leptomeningeal metastasis.

-   Patients with clinically significant cardiac disease (requiring treatment).

-   Patients with synchronous or metachronous multiple primary cancer with a disease-free period ≤3 years at registration.

-   Patients with a history of any of the following therapies:

-   Patients with confirmed HIV infection (those not screened for HIV antibody may register).

    -   Chemotherapy and the last dose of regorafenib received within 14 days before registration.

    -   Cetuximab, panitumumab, bevacizumab, aflibercept, or ramucirumab received within 3 weeks before registration.

    -   Administration of a biological product (excluding cetuximab, panitumumab, bevacizumab, aflibercept and ramucirumab), immunotherapy, or unapproved anticancer drugs within 4 weeks before registration.

    -   Prior radiotherapy targeted to ≥30% of the bone marrow.

    -   Major surgery (excluding minor surgery, such as lymph node biopsy, needle biopsy, or port implantation) within 2 weeks before registration.

-   Patients with positive HBs antigen.

-   Patients diagnosed with hepatic cirrhosis.

-   Pregnant or breastfeeding women.

-   Patients with other medically significant abnormalities.

Endpoints and assessments {#s4}
=========================

The primary endpoint is confirmed objective response rate (ORR) by investigators' assessment. The secondary endpoints are PFS, duration of response (DoR), disease control rate (DCR) by investigators' assessment, overall survival (OS), and incidence of adverse events (AEs). We will evaluate efficacy according to the Response Evaluation Criteria in Solid Tumors (RECIST), V.1.1, using CT scans every 6 weeks plus/minus 1 week for the first three times and every 8 weeks plus/minus 2 weeks from the fourth evaluation onward. We will calculate ORR as the proportion of patients with complete response (CR) or PR. We defined OS as the period from the registration to death from any cause and will censor it at the last day the patient is alive. We defined PFS as the period from the registration to progression or death from any cause and will censor it at the last day when the patient is alive without progression. We defined DoR as the period from the first response to progression or death from any cause and will censor it at the last day when the patient is alive without progression. We will calculate DCR as the proportion of patients with CR, PR, or SD based on RECIST criteria. We will assess AEs according to the Common Terminology Criteria for Adverse Events, V.4.0, before administration of the investigational drug on the administration day. We will assess the same endpoints during the liquid biopsy analysis.

Statistical analysis {#s5}
====================

Since RR has been reported at 0%--11% after second-line and beyond treatments in patients with *BRAF* V600E mutant mCRC, we set a threshold ORR at 5%. Therefore, we calculated a sample size for the primary analysis part at 27 (FAS) using an optimal two-stage design[@R15] with ORR of 25% deemed promising and 5% unacceptable (one-sided α, 0.05; β, 0.1), promising DCR at 70%, threshold DCR at 50%, and Yule's correlation coefficient between ORR and DCR at 0.5. Our planned sample size of the liquid biopsy part is 15 patients at most in an exploratory manner. For the primary analysis cohort, we have planned an interim analysis when the response evaluation for the first 12 patients enrolled becomes available. If we find less than six patients having CR, PR, or SD (ie, the point estimate of DCR by investigators' assessment is \<50%), we plan to discuss on discontinuing the study due to futility; otherwise, we will continue the study. We will confirm the ORR by investigators' assessment and will estimate its 90% CI using the exact binomial method. We plan to meet the primary endpoint if we observe four or more responder patients (ie, ORR ≥14.8%). For the FAS of the primary analysis part, we will present PFS, DoR and DCR by investigators' assessment and OS using appropriate statistical methods. We will tabulate the incidences of AEs in the safety population.

Conclusion {#s6}
==========

The BRAVERY study (EPOC1701) is the first phase II study to evaluate the efficacy and safety of eribulin in patients with *BRAF* V600E mutant mCRC. We anticipate that our findings will contribute to establishing the efficacy and safety of eribulin in this patient population.
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